Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026
Safety Classified by Officially
12 new medicines recommended for approval
EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its September 2026 meeting.
The committee recommended granting a marketing authorisation for Frehemgo (denecimig), for the prophylaxis of bleeding episodes in patients with haemophilia A, an inherited bleeding disorder caused by a lack of factor VIII, a protein that helps blood clot.
Gevalka (ensartinib) received a positive opinion from the CHMP for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer.
The CHMP recommended granting a marketing authorisation for Klygefa (gefurulimab) for the treatment of adult patients with generalised myasthenia gravis, a disease that leads to muscle weakness and tiredness.
The committee adopted a positive opinion for Lifyorli (relacorilant), for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Povofortay (povorcitinib) received a positive opinion from the CHMP for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults. Acne inversa is a chronic inflammatory skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin. Povofortay is the first oral daily treatment that can be prescribed in adults patients refractory or intolerant to anti-tumour necrosis factor therapy.
The CHMP recommended granting a marketing authorisation for Sepalna (senaparib), a maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer.
The committee recommended granting a marketing authorisation for VaxRabeo (rabies virus (inactivated) strain WISTAR (PM/WI38 1503-3M)), a vaccine for pre-exposure and post-exposure prophylaxis against rabies in individuals of all age groups. Rabies is a rare but very serious infection caused by a virus which is usually spread through the bite or scratch of an infected animal.
This is an extract. The publication continues at the source.
Source: European Medicines Agency.
Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2026
Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Medicines Agency — imported from official source
- Official source
- https://www.ema.europa.eu/en/news.xml RSS
- Imported
- October 03, 2026 20:30
- Versions
- 1 recorded
- Identity
-
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human...